查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
癌症干细胞的全球市场:市场规模 - 各癌症，各作用机制，各移植，各用途，各终端用户，各地区展望，竞争策略，各市场区隔预测(～2032年)
市场调查报告书
商品编码
1170429

癌症干细胞的全球市场:市场规模 - 各癌症，各作用机制，各移植，各用途，各终端用户，各地区展望，竞争策略，各市场区隔预测(～2032年)

Cancer Stem Cells Market Size- By Cancer, By Mode Of Action, By Transplantation, By Application, By End User- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 226 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球癌症干细胞的市场规模，预计至2032年达到26亿8,000万美元，以10.29％的年复合成长率成长。

市场扩大的主要原因，是全球癌症罹患率的上升。改变人类DNA的基因工程学，和从干细胞做出三次元结构的组织的类器官技术的出现，在COVID-19间的干细胞研究中大幅发展的2个要素，对全球癌症干细胞市场带来了好影响。

本报告提供全球癌症干细胞市场相关调查，市场动态，市场变数与展望，各癌症、作用机制、移植、用途、最终用途、地区的市场分析，企业简介等相关资讯。

目录

第1章 简介

  • 调查范围
  • 市场区隔分析

第2章 调查手法

  • 调查资料来源
  • 市场规模的估计
  • 资料的三角测量

第3章 摘要整理

第4章 市场动态

  • 促进因素，阻碍因素，机会，及课题分析
    • 促进因素
    • 阻碍因素
    • 机会
    • 课题
  • 全球癌症干细胞市场上COVID-19的影响

第5章 市场变数与展望

  • SWOT分析
    • 优势
    • 弱点
    • 机会
    • 威胁
  • PESTEL分析
    • 政治形势
    • 经济形势
    • 社会形势
    • 技术形势
    • 环境形势
    • 法律上的形势
  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 替代品的威胁
    • 新加入厂商的威胁
    • 竞争企业间的敌对关係
  • 热图分析

第6章 全球癌症干细胞市场:各癌症(2019年～2032年(100万美元))

  • 急性白血病
  • 再生不良性贫血
  • 慢性淋巴性白血病
  • 骨质疏鬆症

第7章 全球癌症干细胞市场:各作用机制(2019年～2032年(100万美元))

  • 作为标的癌症干细胞
    • 各抗CSC治疗药物
    • 产品
  • 干细胞为基础的癌症治疗
    • 自体SC移植
    • 同类SC移植

第8章 全球癌症干细胞市场:各移植(2019年～2032年(100万美元))

  • 异体干细胞治疗
  • 自体干细胞治疗

第9章 全球癌症干细胞市场:各用途(2019年～2032年(100万美元))

  • 血液癌症
  • 乳癌
  • 子宫颈癌症
  • 大肠癌症
  • 肺癌症
  • 前列腺癌症

第10章 全球癌症干细胞市场:各最终用途(2019年～2032年(100万美元))

  • 细胞库、组织银行
  • 医院、手术用检验室
  • 製药企业、生物医学企业

第11章 全球癌症干细胞市场:各地区(2019年～2032年(100万美元))

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 其他的亚太地区
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中东、非洲
    • 沙乌地阿拉伯王国
    • 阿拉伯联合大公国
    • 其他的中东、非洲

第12章 企业简介

  • AbbVie Inc.
    • 企业概要
    • 财务展望
    • 产品概要
    • 最近的开发
  • Advanced Cell Diagnostics Inc.
  • Bionomic
  • BioNTech
  • BioTime Inc.
  • Caladrius Biosciences Inc.
  • Celgene Corp.
  • ExCellThera
  • Gamida Cell
  • Irvine Scientific
  • Lonza
  • MacroGenics Inc.
  • Menarini Group
  • Merck KGaA
  • Mereo BioPharma
  • Miltenyi Biotec
  • PromoCell GmbH
  • Propanc Biopharma
  • Silicon Biosystems
  • Sino Biological Inc.
  • Thermo Fisher Scientific Inc.
  • VIaCyte Inc.
简介目录
Product Code: HLCA2220

Global Cancer Stem Cells Market Overview:

According to SPER Market Research, the Global Cancer Stem Cells Market is estimated to reach USD 2.68 billion by 2032 with a CAGR of 10.29%.

The tumour's other cell types are produced by the cancer cell, which has the capacity to divide and grow continuously. Cancer stem cells are believed to oversee tumour development, metastasis, and recurrence. These are the rare forms of godlike cells called cancer stem cells are found in tumours and give rise to a wide range of cell types that make up the tumour. These cells have been identified in several human tumours and may serve as targets for cancer therapy. Most anti-cancer medications function by inducing the death of cancer cells. Even though these treatments seem to be working, some individuals nonetheless have a disease recurrence. The primary driver fuelling the expansion of the cancer stem cell market is the rising incidence of cancer in the world.

Impact of COVID-19 on the Global Cancer Stem Cells Market:

The cancer stem cell sector has prospered from the COVID-19 epidemic. The advent of genetic engineering, which modifies human DNA, and organoid technology, which creates the three-dimensional structure of the tissue from originating stem cells, are two of the most significant strides in stem cell research during COVID-19. The advent of genetic engineering, which modifies human DNA, and organoid technology, which creates the three-dimensional structure of the tissue from stem cells, have been two of the most important strides in stem cell research during COVID-19. This element had a favourable effect on the world market for cancer stem cells. Additionally, there has been an increase in the use of allogeneic stem cell therapy and hematopoietic cell transplantation (HCT), particularly among cancer patients who have COVID-19 infections.

Scope of the Report:

Report Metric Details:

  • Market size available for years: 2019-2032
  • Base year considered: 2021
  • Forecast period: 2022-2032
  • Segments covered: By Cancer, By Mode Of Action, By Transplantation, By Application, By End User
  • Regions covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa
  • Companies Covered: AbbVie Inc., Advanced Cell Diagnostics Inc., Bionomics, BioNTech, BioTime Inc., Caladrius Biosciences Inc., Celgene Corp., ExCellThera, Gamida Cell, Irvine Scientific, Lonza, MacroGenics, Inc., Menarini Group, Merck KGaA, Mereo BioPharma, Miltenyi, Biotec, PromoCell GmbH, Propanc Biopharma, Silicon Biosystems, Sino Biological Inc., Thermo Fisher Scientific Inc., ViaCyte Inc.

Global Cancer Stem Cells Market Segmentation:

  • By Caner: Based on the Caner, Global Cancer Stem Cells Market is segmented as; Acute Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia, Osteopetrosis.
  • By Mode Of Action: Based on the Mode Of Action, Global Cancer Stem Cells Market is segmented as; Targeted Cancerous Stem Cells {By Anti-CSC Therapeutics (Pathway Inhibitors, Surface Marker Based, Immuno-evasion and Targeting Tumour Microenvironment, Nanoparticle-based Therapies), Products (Cell-Culturing, Cell-Separation, Cell-Analysis, Molecular Analysis)}, Stem Cell Based Cancer Therapy (Autologous SC Transplant, Allogeneic SC Transplant).
  • By Transplantation: Based on the Transplantation, Global Cancer Stem Cells Market is segmented as; Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy.
  • By Application: Based on the Application, Global Cancer Stem Cells Market is segmented as; Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer.
  • By End User: Based on the End Use, Global Cancer Stem Cells Market is segmented as; Hospitals and surgical laboratories, Cell banks and tissue banks, Pharmaceutical and biomedical companies.
  • By Region: Due to improvements in healthcare infrastructure and strong reimbursement policies across the region, North America had the substantial share, accounting for more than two-fifths of the worldwide cancer stem cell market. On the other hand, the Asia-Pacific area will have the fastest growth in the following years. This is because the governments of China, Japan, and India are developing regulations for the development of stem cell research facilities and investing in healthcare infrastructure.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity, and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Cancer Stem Cells Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Cancer Stem Cells Market, By Cancer, 2019-2032 (USD Million)

  • 6.1. Acute Leukemia
  • 6.2. Aplastic Anemia
  • 6.3. Chronic Lymphocytic Leukemia
  • 6.4. Osteopetrosis

7. Global Cancer Stem Cells Market, By Mode Of Action, 2019-2032 (USD Million)

  • 7.1 Targeted Cancerous Stem Cells
    • 7.1.1 By Anti-CSC Therapeutics
      • 7.1.1.1 Pathway Inhibitors
      • 7.1.1.2 Surface Marker Based
      • 7.1.1.3 Immuno-evasion and Targeting Tumour Microenvironment
      • 7.1.1.4 Nanoparticle-based Therapies
    • 7.1.2 Products
      • 7.1.2.1 Cell-Culturing
      • 7.1.2.2 Cell-Separation
      • 7.1.2.3 Cell-Analysis
      • 7.1.2.4 Molecular Analysis
  • 7.2 Stem Cell Based Cancer Therapy
    • 7.2.1 Autologous SC Transplant
    • 7.2.2 Allogeneic SC Transplant

8. Global Cancer Stem Cells Market, By Transplantation, 2019-2032 (USD Million)

  • 8.1. Allogeneic Stem Cell Therapy
  • 8.2. Autologous Stem Cell Therapy

9. Global Cancer Stem Cells Market, By Application, 2019-2032 (USD Million)

  • 9.1. Blood Cancer
  • 9.2. Breast Cancer
  • 9.3. Cervical Cancer
  • 9.4. Colorectal Cancer
  • 9.5. Lung Cancer
  • 9.6. Prostate Cancer

10. Global Cancer Stem Cells Market, By End Use, 2019-2032 (USD Million)

  • 10.1 Cell Banks and Tissue Banks
  • 10.2 Hospital and Surgical Laboratories
  • 10.3 Pharmaceutical and Biomedical Companies

11. Global Cancer Stem Cells Market, By Region, 2019-2032 (USD Million)

  • 11.1 North America
    • 11.1.1. United States
    • 11.1.2. Canada
    • 11.1.3. Mexico
  • 11.2 Europe
    • 11.2.1. Germany
    • 11.2.2. United Kingdom
    • 11.2.3. France
    • 11.2.4. Italy
    • 11.2.5. Spain
    • 11.2.6. Rest of Europe
  • 11.3 Asia-Pacific
    • 11.3.1. China
    • 11.3.2. Japan
    • 11.3.3. India
    • 11.3.4. Australia
    • 11.3.5. South Korea
    • 11.3.6. Rest of Asia-Pacific
  • 11.4 South America
    • 11.4.1. Brazil
    • 11.4.2. Argentina
    • 11.4.3. Rest of South America
  • 11.5 Middle East & Africa
    • 11.5.1. Kingdom of Saudi Arabia
    • 11.5.2. United Arab Emirates
    • 11.5.3. Rest of Middle East & Africa

12. Company Profiles

  • 12.1 AbbVie Inc.
    • 12.1.1. Company details
    • 12.1.2. Financial outlook
    • 12.1.3. Product summary
    • 12.1.4. Recent developments
  • 12.2 Advanced Cell Diagnostics Inc.
    • 12.2.1. Company details
    • 12.2.2. Financial outlook
    • 12.2.3. Product summary
    • 12.2.4. Recent developments
  • 12.3 Bionomics
    • 12.3.1. Company details
    • 12.3.2. Financial outlook
    • 12.3.3. Product summary
    • 12.3.4. Recent developments
  • 12.4 BioNTech
    • 12.4.1. Company details
    • 12.4.2. Financial outlook
    • 12.4.3. Product summary
    • 12.4.4. Recent developments
  • 12.5 BioTime Inc.
    • 12.5.1. Company details
    • 12.5.2. Financial outlook
    • 12.5.3. Product summary
    • 12.5.4. Recent developments
  • 12.6 Caladrius Biosciences Inc.
    • 12.6.1. Company details
    • 12.6.2. Financial outlook
    • 12.6.3. Product summary
    • 12.6.4. Recent developments
  • 12.7 Celgene Corp.
    • 12.7.1. Company details
    • 12.7.2. Financial outlook
    • 12.7.3. Product summary
    • 12.7.4. Recent developments
  • 12.8 ExCellThera
    • 12.8.1. Company details
    • 12.8.2. Financial outlook
    • 12.8.3. Product summary
    • 12.8.4. Recent developments
  • 12.9 Gamida Cell
    • 12.9.1. Company details
    • 12.9.2. Financial outlook
    • 12.9.3. Product summary
    • 12.9.4. Recent developments
  • 12.10 Irvine Scientific
    • 12.10.1. Company details
    • 12.10.2. Financial outlook
    • 12.10.3. Product summary
    • 12.10.4. Recent developments
  • 12.11 Lonza
    • 12.11.1. Company details
    • 12.11.2. Financial outlook
    • 12.11.3. Product summary
    • 12.11.4. Recent developments
  • 12.12 MacroGenics Inc.
    • 12.12.1. Company details
    • 12.12.2. Financial outlook
    • 12.12.3. Product summary
    • 12.12.4. Recent developments
  • 12.13 Menarini Group
    • 12.13.1. Company details
    • 12.13.2. Financial outlook
    • 12.13.3. Product summary
    • 12.13.4. Recent developments
  • 12.14 Merck KGaA
    • 12.14.1. Company details
    • 12.14.2. Financial outlook
    • 12.14.3. Product summary
    • 12.14.4. Recent developments
  • 12.15 Mereo BioPharma
    • 12.15.1. Company details
    • 12.15.2. Financial outlook
    • 12.15.3. Product summary
    • 12.15.4. Recent developments
  • 12.16 Miltenyi Biotec
    • 12.16.1. Company details
    • 12.16.2. Financial outlook
    • 12.16.3. Product summary
    • 12.16.4. Recent developments
  • 12.17 PromoCell GmbH
    • 12.17.1. Company details
    • 12.17.2. Financial outlook
    • 12.17.3. Product summary
    • 12.17.4. Recent developments
  • 12.18 Propanc Biopharma
    • 12.18.1. Company details
    • 12.18.2. Financial outlook
    • 12.18.3. Product summary
    • 12.18.4. Recent developments
  • 12.19 Silicon Biosystems
    • 12.19.1. Company details
    • 12.19.2. Financial outlook
    • 12.19.3. Product summary
    • 12.19.4. Recent developments
  • 12.20 Sino Biological Inc.
    • 12.20.1. Company details
    • 12.20.2. Financial outlook
    • 12.20.3. Product summary
    • 12.20.4. Recent developments
  • 12.21 Thermo Fisher Scientific Inc.
    • 12.21.1. Company details
    • 12.21.2. Financial outlook
    • 12.21.3. Product summary
    • 12.21.4. Recent developments
  • 12.22 VIaCyte Inc.
    • 12.22.1. Company details
    • 12.22.2. Financial outlook
    • 12.22.3. Product summary
    • 12.22.4. Recent developments